A Phase 4 interventional study of Pneumococcal polysaccharide vaccine and pneumococcal conjugate vaccine in Pneumococcal Pneumonia, sponsored by Helsinki University Central Hospital. Completed at 4 sites in Finland. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-07-26.
Sponsored by Helsinki University Central Hospital · Phase 4, Interventional, and Prevention
Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study aims to compare lymphocyte homing in pneumonia and in those receiving Pnc polysaccharide vaccine (PPV) or Pnc conjugate vaccine (PCV)
Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study compares the homing profiles of Pnc-specific plasmablasts in 15 patients with pneumonia and in 15 volunteers receiving Pnc polysaccharide vaccine (PPV) and 12 volunteers receiving Pnc conjugate vaccine (PCV)
122 studies on the registry are indexed under Pneumonia, Pneumococcal; 7 are open to participants now.
This study's enrollment of 42 is below the median of 304 across 80 interventional studies indexed under Pneumonia, Pneumococcal.
Browse Pneumonia, Pneumococcal studies →Helsinki University Central Hospital is the lead sponsor of 311 studies on the registry; 61 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with Pnc pneumonia
Volunteers immunized with Pnc polysaccharide vaccine
Biological: Pneumococcal polysaccharide vaccine
Volunteers immunized with Pnc conjugate vaccine
Biological: pneumococcal conjugate vaccine
Pneumococcal polysaccharide vaccine 0.5 ml i.m.
Also known as: Pneumovax
pneumococcal conjugate vaccine 0.5 ml i.m.
Also known as: Prevenar
Expression of homing receptors on circulating plasmablasts in Pnc pneumonia and after vaccination
HR on circulating Pnc-specific plasmablasts are determined in patients with pneumonia on day 7-10, in vaccinees on days 0 and 7
Time frame: Day 0 and Day 7-10
The record gives a start of Jan 2005, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal Conjugate Vaccine
Helsinki University Central Hospital →